Madrigal Pharmaceuticals is a biopharmaceutical company focused on metabolic and liver disease, best known for resmetirom (Rezdiffra), a therapy approved for metabolic dysfunction–associated steatohepatitis (MASH) with liver fibrosis. Its commercial model centers on a specialized prescription drug rather than a broad multi-product portfolio. The company targets hepatologists, gastroenterologists, and patients with progressive fatty-liver disease who previously had few approved drug options.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 137.3 | — | -73.2 | — |
| Q2 2025 | 212.8 | — | -42.3 | — |
| Q3 2025 | 287.3 | — | -114.2 | — |
| Q4 2025 | 321.1 | — | -58.6 | — |
| Q1 2026 | 311.3 | 126.8% | -94.4 | — |
| Q2 2026 | 364.3 | 71.2% | -57.9 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Amkor Technology, Inc. (AMKR), AGNC Investment Corp. (AGNC), The Ensign Group, Inc. (ENSG), Nova Ltd. (NVMI), Domino's Pizza, Inc. (DPZ), Popular, Inc. (BPOP)